RIT Oncology Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 2

RIT Oncology General Information

Description

Marketer of pharmaceutical preparations. The company commercializes and develops ZEVALIN(R) ([90Y]-ibritumomab tiuxetan), which is a radioimmunotherapeutic drug, used for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma and patients who have rituximab-refractory follicular non-Hodgkin's lymphoma.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Corporate Office
  • 501 Elliott Avenue West
  • Suite 400
  • Seattle, WA 98119
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

RIT Oncology Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore RIT Oncology‘s full profile, request access.

Request a free trial

RIT Oncology Patents

RIT Oncology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-6207858-B1 Eliminates the need for ion exchange chromotographic separation of intermediates, useful as bi-functional chelators in radioimmunotherapy and imaging, diethylenetriaminepentaacetic acid (dtpa), suitable for Inactive 03-Mar-1999 0000000000 0
US-7608241-B2 For testing the clinical efficacy of therapeutic antibodies for the treatment/imaging of tumors and tumor cells; mixing chelator-conjugated antibody with solution containing radiolabel, incubating mixture to produce radiolabeled antibody which may be administered directly to a human patient Inactive 01-Mar-1999 0000000000 00
US-20060067884-A1 For radiolabeling proteins, peptides and ligands with therapeutic radioisotopes such that these radiolabeled agents may be administered directly to patients without the need for additional purification; for the treatment of cancer Active 01-Mar-1999 0000000000 00
US-7229620-B2 For radiolabeling proteins, peptides and ligands with therapeutic radioisotopes such that these radiolabeled agents may be administered directly to patients without the need for additional purification; for the treatment of cancer Inactive 01-Mar-1999 0000000000 00
US-6994840-B1 For radiolabeling proteins, peptides and ligands with therapeutic radioisotopes such that these radiolabeled agents may be administered directly to patients without the need for additional purification; for the treatment of cancer Inactive 01-Mar-1999 G01N33/534 00
To view RIT Oncology’s complete patent history, request access »

RIT Oncology Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore RIT Oncology‘s full profile, request access.

Request a free trial

RIT Oncology FAQs

  • When was RIT Oncology founded?

    RIT Oncology was founded in 2008.

  • Where is RIT Oncology headquartered?

    RIT Oncology is headquartered in Seattle, WA.

  • What industry is RIT Oncology in?

    RIT Oncology’s primary industry is Drug Discovery.

  • Is RIT Oncology a private or public company?

    RIT Oncology is a Private company.

  • What is the current valuation of RIT Oncology?

    The current valuation of RIT Oncology is 0000.

  • What is RIT Oncology’s current revenue?

    The current revenue for RIT Oncology is 000000.

  • Who are RIT Oncology’s investors?

    CTI BioPharma has invested in RIT Oncology.

  • When was RIT Oncology acquired?

    RIT Oncology was acquired on 15-Mar-2009.

  • Who acquired RIT Oncology?

    RIT Oncology was acquired by Spectrum Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »